Skip to content
Search

Latest Stories

Alliance Pharma founder donates £5m to create University of Sunderland's new drug research centre

John Dawson, the founder and former CEO of Alliance Pharma, has donated £5million to the University of Sunderland towards the creation of a new drug research centre.

The donation – the biggest in the university’s history – will create the John Dawson Drug Discovery and Development Research Institute to improve health and wellbeing of millions of people worldwide.


The new centre has been named after the pharmaceutical entrepreneur and Sunderland graduate who, alongside wife Sam, has provided the funding.

He and Sam were on Thursday (April 20) joined by specially invited guests from across the region’s health, education, and business communities, to launch the Institute housed in the University’s Sciences Complex.

2023pr047pic4 John Dawson and his wife Sam outside the John Dawson Drug Discovery and Development Research Institute at the University of Sunderland’s City Campus. Picture: DAVID WOOD

Unveiling a plaque inside the building, John said: “It’s an absolute honour and privilege to be able to launch the new Drug Discovery and Development Research Institute at the University of Sunderland today.

“It’s been wonderful to be back on the campus and see the incredible developments that have taken place since I studied pharmacy here more than 50 years ago.

“I was immediately impressed at what has been achieved in that intervening half-century and I’ve been delighted to assist the University continue its development, particularly in the health arena.

“I hope the launch of this institute will mark the next phase in the University’s evolution and I’m very much looking forward to working with the team as they bring their projects to fruition.”

The new institute will play a key role in turning laboratory research and innovation into life-changing therapies for clinical practice, working closely with the NHS and the pharmaceutical industry.

It will also bring together expertise in clinical, laboratory and data science to address issues of local, national and international importance and focus on on areas including the discovery of new medicines for the treatment of rare inherited metabolic diseases -- developing targeted delivery methods and technologies to improve pharmaceutical manufacturing processes as well as the development and application of machine learning tools for early disease detection.

2023pr047pic3 John Dawson and his wife Sam pictured with the university's vice chancellor and chief executive Sir David Bell (L). Picture: DAVID WOOD

Sir David Bell, Newcastle University’s vice-chancellor and chief executive, said: “I am enormously grateful to John and Sam Dawson for their immense generosity in supporting this new Research Institute in the crucially important fields of drug discovery and development.

"The fact that John is ‘one of us’ is an added bonus as his life and career demonstrate the good that our graduates do in so many different walks of life.”

After graduating from Sunderland Polytechnic in 1970, Newcastle-born John went on to build a successful career in the pharmaceutical industry. He founded the prescription medicines and consumer healthcare company, Alliance Pharma, in 1996.

Commenced trading in 1998 with just two full-time employees in the UK, the company expanded over the next 20 years. John turned it into an international pharmaceutical powerhouse with sales now exceeding £170m, operating out of nine offices in eight countries with more than 280 employees.

He stepped down from Alliance Pharma in 2019.

More For You

Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less
13 pharmacists achieve RPS core advanced credential with record pass rate

The latest successful cohort includes pharmacists from both England and Scotland.

Pic credit: Getty Images

13 more pharmacists achieve RPS core advanced credential - Highest pass rate yet

The Royal Pharmaceutical Society (RPS) has announced that 13 more pharmacists have successfully completed Core Advanced Credentialling as part of the latest assessment cohort —achieving a remarkable 93% pass rate, the highest to date.

This brings the total number of pharmacists awarded the RPS core advanced credential to 113 since the launch of the Core Advanced Curriculum in 2023, with successful candidates from GP, secondary care and community settings.

Keep ReadingShow less